Black Diamond Therapeutics (BDTX)
NASDAQ:BDTX
Total Valuation
Black Diamond Therapeutics has a market cap or net worth of $136.92M. The enterprise value is $131.00M.
Market Cap$136.92M
Enterprise Value$131.00M
Share Statistics
Black Diamond Therapeutics has 57,288,750 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding57,288,750
Owned by Insiders13.86%
Owned by Institutions21.91%
Financial Efficiency
Black Diamond Therapeutics’s return on equity (ROE) is 0.20 and return on invested capital (ROIC) is 15.61%.
Return on Equity (ROE)0.20
Return on Assets (ROA)0.16
Return on Invested Capital (ROIC)15.61%
Return on Capital Employed (ROCE)0.16
Revenue Per Employee2.92M
Profits Per Employee931.96K
Employee Count24
Asset Turnover0.49
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Black Diamond Therapeutics is 6.2. Black Diamond Therapeutics’s PEG ratio is -0.05.
PE Ratio6.2
PS Ratio1.97
PB Ratio1.23
Price to Fair Value1.23
Price to FCF4.67
Price to Operating Cash Flow4.61
PEG Ratio-0.05
Income Statement
In the last 12 months, Black Diamond Therapeutics had revenue of 70.00M and earned 22.37M in profits. Earnings per share was 0.39.
Revenue70.00M
Gross Profit69.67M
Operating Income19.87M
Pretax Income22.37M
Net Income22.37M
EBITDA20.20M
Earnings Per Share (EPS)0.39
Cash Flow
In the last 12 months, operating cash flow was 29.61M and capital expenditures 0.00, giving a free cash flow of 29.61M billion.
Operating Cash Flow29.61M
Free Cash Flow29.61M
Free Cash Flow per Share0.52
Dividends & Yields
Black Diamond Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.10
52-Week Price Change75.74%
50-Day Moving Average2.31
200-Day Moving Average2.93
Relative Strength Index (RSI)58.34
Average Volume (3m)634.88K
Important Dates
Black Diamond Therapeutics upcoming earnings date is May 13, 2026, Before Open (Confirmed).
Last Earnings DateMar 16, 2026
Next Earnings DateMay 13, 2026
Ex-Dividend Date―
Financial Position
Black Diamond Therapeutics as a current ratio of 8.42, with Debt / Equity ratio of 13.43%
Current Ratio8.42
Quick Ratio8.42
Debt to Market Cap0.00
Net Debt to EBITDA-0.29
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Black Diamond Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Black Diamond Therapeutics EV to EBITDA ratio is 6.55, with an EV/FCF ratio of 4.47.
EV to Sales1.89
EV to EBITDA6.55
EV to Free Cash Flow4.47
EV to Operating Cash Flow4.47
Balance Sheet
Black Diamond Therapeutics has $128.65M in cash and marketable securities with $15.07M in debt, giving a net cash position of $113.58M billion.
Cash & Marketable Securities$128.65M
Total Debt$15.07M
Net Cash$113.58M
Net Cash Per Share$1.98
Tangible Book Value Per Share$1.97
Margins
Gross margin is 99.78%, with operating margin of 28.39%, and net profit margin of 31.95%.
Gross Margin99.78%
Operating Margin28.39%
Pretax Margin31.95%
Net Profit Margin31.95%
EBITDA Margin28.85%
EBIT Margin28.39%
Analyst Forecast
The average price target for Black Diamond Therapeutics is $10.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$10.00
Price Target Upside318.41% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast―